BioNTech SE (BNTX) Gains from Sales and Divestitures (2020 - 2023)

BioNTech SE has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $4.1 million for Q4 2023.

• Gains from Sales and Divestitures for Q4 2023 came in at $4.1 million, up 567.91% year-over-year; the trailing twelve-month figure through Dec 2023 was $4.1 million (up 567.91% YoY), and the FY2023 annual result was $4.1 million, up 567.91% from the prior year.
• Gains from Sales and Divestitures came in at $4.1 million for Q4 2023 at BioNTech SE, up from $3.9 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $5.3 million in Q4 2021 to a low of $213411.3 in Q2 2022.
• The 4-year median for Gains from Sales and Divestitures is $541931.7 (2022), against an average of $1.6 million.
• Across the five-year window, Gains from Sales and Divestitures sank 88.37% in 2022 and jumped 871.69% in 2023, its largest moves.
• BioNTech SE's Gains from Sales and Divestitures stood at $715373.9 in 2020, then soared by 635.6% to $5.3 million in 2021, then tumbled by 88.37% to $612148.4 in 2022, then soared by 567.91% to $4.1 million in 2023.
• The last three Gains from Sales and Divestitures figures came in at $4.1 million (Q4 2023), $3.9 million (Q3 2023), and $326677.3 (Q2 2023), per Business Quant data.